Recent clinical trials such as CRUISE and BRAVO have shown that the immediate monthly injections of anti VEGF (Ranibizumab) during the first 6 months and then later as needed decreased substantially the time to achieve visual acuity gain following CRVO5. In BRAVO trial the cumulative proportion of patients who had gained 15 letters or more from baseline by 12 month (from CRVO incidence) was 50% (sham), 68% (ranibizumab 0.3 mg), and 71% (ranibizumab 0.5 mg) and in CRUISE trial 42%, 61%, and 66%, respectively.